This Unusual “Rogue DNA” Allows Some Cancers to Thrive—and Scientists Just Found Its Achilles’ Heel

Automatically curated summary from The Debrief.

According to a study published in Nature by Memorial Sloan Kettering Cancer Center researchers, extrachromosomal DNA (ecDNA)—which drives growth in roughly one in six human cancers—possesses a built-in fragility at repetitive TA structures. The team observed that cancer cells rely on proteins FANCM and Polθ to repair these fragile points. Inhibiting Polθ with experimental drugs destabilized ecDNA across prostate, gastric, and colorectal cancer cell lines while sparing normal cells. Although Polθ inhibitors are in clinical development, researchers stress that further studies are necessary before applying this approach in treatments.

Context and limitations

Findings are based on laboratory research involving cell lines; effectiveness and safety of targeting ecDNA in human patients remain unproven and require clinical evaluation.